Jennifer Ku to Cohort Studies
This is a "connection" page, showing publications Jennifer Ku has written about Cohort Studies.
Connection Strength
0.436
-
Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study. Vaccine. 2023 06 29; 41(29):4212-4219.
Score: 0.139
-
Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study. Vaccine. 2023 06 01; 41(24):3636-3646.
Score: 0.138
-
mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States. Nat Commun. 2023 09 20; 14(1):5851.
Score: 0.035
-
Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):643-649.
Score: 0.034
-
Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study. PLoS One. 2022; 17(4):e0267824.
Score: 0.032
-
Long-Term Outcomes in a Population-based Cohort with Respiratory Nontuberculous Mycobacteria Isolation. Ann Am Thorac Soc. 2017 07; 14(7):1120-1128.
Score: 0.023
-
The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J. 2015 Apr; 45(4):1177-9.
Score: 0.019
-
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol. 2013 Jan; 155(1):183-189.e1.
Score: 0.016